Randomised controlled trial of GM-CSF in critically ill patients with impaired neutrophil phagocytosis

Abstract

GM-CSF did not improve mean neutrophil phagocytosis at day 2, but was safe and appeared to increase the proportion of patients with adequate phagocytosis. The study suggests proof of principle for a pharmacological effect on neutrophil function in a subset of critically ill patients.